CordenPharma Constructs New Peptide Manufacturing Facility in Switzerland
Introduction:
CordenPharma is investing over US$540 million (€500 million) to construct a new peptide manufacturing facility in Muttenz, Switzerland.
Features:
The facility, located at Getec Park near Basel, is designed for small, medium, and large-scale peptide production.
The site will house Solid Phase Peptide Synthesis (SPPS) reactors with a total capacity exceeding 5,000 litres.
Advanced automation, digitalisation, and cutting-edge manufacturing technologies will ensure compliance with stringent regulatory requirements, including Biologics License Application (BLA) standards.
The project supports sustainability with closed-loop energy and material cycles, as well as innovative waste-to-value streams.
Construction and qualification phases will take place from 2025 to 2027, with commercial production set to begin in the first half of 2028.
In parallel, CordenPharma is expanding its Boulder, Colorado facility in the United States, increasing its total SPPS reactor capacity to over 42,000 litres by 2028.
Specifications:
| Name | CordenPharma |
| Type | New Construction |
| Budget | US$540 million (€500 million+) |
| Year | 2028 |
